GT Biopharma, Inc.
GTBP
$5.98
$0.7414.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -4.52M | -2.83M | -23.03M | -3.11M | -30.17M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 46.00K | 35.00K | 17.37M | 147.00K | 27.70M |
| Change in Net Operating Assets | 212.00K | 330.00K | 1.64M | -710.00K | -545.00K |
| Cash from Operations | -4.26M | -2.47M | -4.02M | -3.68M | -3.01M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 577.00K | 4.44M | 0.00 | 436.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 297.00K | 4.00M | 4.01M | 1.06M | 5.44M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -144.00K | -85.00K | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 297.00K | 4.58M | 8.31M | 977.00K | 5.88M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.96M | 2.11M | 4.28M | -2.70M | 2.86M |